Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer
Abstract Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14997 |
| _version_ | 1797755847898562560 |
|---|---|
| author | Jhe‐Cyuan Guo Chia‐Lang Hsu Min‐Shu Hsieh Chia‐Chi Lin Ta‐Chen Huang Hung‐Yang Kuo Yu‐Yun Shao Chih‐Hung Hsu |
| author_facet | Jhe‐Cyuan Guo Chia‐Lang Hsu Min‐Shu Hsieh Chia‐Chi Lin Ta‐Chen Huang Hung‐Yang Kuo Yu‐Yun Shao Chih‐Hung Hsu |
| author_sort | Jhe‐Cyuan Guo |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient. |
| first_indexed | 2024-03-12T17:53:01Z |
| format | Article |
| id | doaj.art-de78700a496347f09d35ff706fccb537 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-12T17:53:01Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-de78700a496347f09d35ff706fccb5372023-08-03T01:12:13ZengWileyThoracic Cancer1759-77061759-77142023-08-0114222216222110.1111/1759-7714.14997Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancerJhe‐Cyuan Guo0Chia‐Lang Hsu1Min‐Shu Hsieh2Chia‐Chi Lin3Ta‐Chen Huang4Hung‐Yang Kuo5Yu‐Yun Shao6Chih‐Hung Hsu7Department of Medical Oncology National Taiwan University Cancer Center Taipei TaiwanDepartment of Medical Research National Taiwan University Hospital Taipei TaiwanDepartment of Pathology National Taiwan University Cancer Center Taipei TaiwanDepartment of Medical Oncology National Taiwan University Cancer Center Taipei TaiwanDepartment of Oncology National Taiwan University Hospital Taipei TaiwanDepartment of Oncology National Taiwan University Hospital Taipei TaiwanDepartment of Oncology National Taiwan University Hospital Taipei TaiwanDepartment of Medical Oncology National Taiwan University Cancer Center Taipei TaiwanAbstract Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.https://doi.org/10.1111/1759-7714.14997differential responseesophageal squamous cell carcinomaimmune checkpoint inhibitorimmune contexturetumor site specific |
| spellingShingle | Jhe‐Cyuan Guo Chia‐Lang Hsu Min‐Shu Hsieh Chia‐Chi Lin Ta‐Chen Huang Hung‐Yang Kuo Yu‐Yun Shao Chih‐Hung Hsu Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer Thoracic Cancer differential response esophageal squamous cell carcinoma immune checkpoint inhibitor immune contexture tumor site specific |
| title | Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer |
| title_full | Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer |
| title_fullStr | Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer |
| title_full_unstemmed | Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer |
| title_short | Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer |
| title_sort | different immune contextures underlie tumor site specific responses to immune checkpoint blockade in esophageal cancer |
| topic | differential response esophageal squamous cell carcinoma immune checkpoint inhibitor immune contexture tumor site specific |
| url | https://doi.org/10.1111/1759-7714.14997 |
| work_keys_str_mv | AT jhecyuanguo differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT chialanghsu differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT minshuhsieh differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT chiachilin differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT tachenhuang differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT hungyangkuo differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT yuyunshao differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer AT chihhunghsu differentimmunecontexturesunderlietumorsitespecificresponsestoimmunecheckpointblockadeinesophagealcancer |